Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana (Q37942538)

25 August 2017

title

Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana (English)

1 reference

25 August 2017

0 references

0 references

anti-retroviral agent

0 references

author name string

Michael Tolle

1

1 reference

25 August 2017

Leigh Howard

2

1 reference

25 August 2017

Brianna Kirk

3

1 reference

25 August 2017

Andres Gomila

4

1 reference

25 August 2017

Heidi Schwarzwald

5

1 reference

25 August 2017

Gabriel Anabwani

6

1 reference

25 August 2017

publication date

4 October 2011

1 reference

Journal of the International Association of Providers of AIDS Care

25 August 2017

published in

1 reference

25 August 2017

volume

11

1 reference

25 August 2017

issue

4

1 reference

25 August 2017

page(s)

260-268

1 reference

Prevalence of primary drug resistance-associated mutations among HIV type 1 vertically Infected children in Belo Horizonte, Brazil

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1545109711422273

Diversity and prevalence of antiretroviral genotypic resistance mutations among HIV-1-infected children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109711422273

Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109711422273

Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109711422273

Antiretroviral drug resistance among HIV-1 infected children failing treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109711422273

Molecular characterization of non-subtype C and recombinant HIV-1 viruses from Cape Town, South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109711422273

The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109711422273

Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109711422273

HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109711422273

Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109711422273

Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109711422273

Viraemia and HIV-1 drug resistance mutations among patients receiving antiretroviral treatment in Mozambique

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109711422273

Prevalence of the K65R resistance reverse transcriptase mutation in different HIV-1 subtypes in Israel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109711422273

The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109711422273

High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109711422273

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109711422273

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109711422273

A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109711422273

Sequencing of antiretroviral therapy in children in low- and middle-income countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109711422273

Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109711422273

Predicted susceptibility of etravirine in HIV patients experiencing virological failure secondary to non-nucleoside reverse transcriptase inhibitor resistance in Argentina

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109711422273

Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109711422273

Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109711422273

Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109711422273

Factors affecting template usage in the development of K65R resistance in subtype C variants of HIV type-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109711422273

The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109711422273

Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109711422273

Analysis of RT sequences of subtype C HIV-type 1 isolates from indian patients at failure of a first-line treatment according to clinical and/or immunological WHO guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109711422273

Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naive chronic and acute HIV-1 subtype C infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109711422273

Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109711422273

21 January 2018

Identifiers

DOI

10.1177/1545109711422273

1 reference

25 August 2017

1 reference